brain-cancer
Canadian researchers discovered that specific brain support cells can send signals that strengthen glioblastoma cancer cells and help tumors grow. When researchers blocked this cellular communication pathway, tumor growth slowed dramatically in preclinical experiments.
brain-cancer
Temozolomide (TMZ) is the standard chemotherapy for glioblastoma (GBM), but its efficacy is limited partly by the P-glycoprotein (ABCB1) efflux transporter at the blood-brain barrier. This systematic review of 4 studies (400+ patients) examined whether ABCB1 gene polymorphisms predict TMZ response…
brain-cancer
Primary central nervous system lymphoma (PCNSL) is treated primarily with high-dose methotrexate (HD-MTX), but new agents presented at ASH 2025 are changing this paradigm. This editorial review summarizes key highlights: BTK inhibitors, immunomodulators, selinexor (an XPO1 inhibitor), and anti-PD-1…
brain-cancer
Glioblastoma (GBM) remains one of the deadliest cancers with only 15-month median survival. Its immunosuppressive tumor microenvironment—shaped partly by prostaglandin E2 (PGE2) produced via the COX-2 pathway—severely limits immunotherapy efficacy.
brain-cancer
Using GEO database gene expression profiles and the FerrDb ferroptosis gene database, 10 hub genes were identified in glioma: TP53, RRM2, EZH2, CDKN1A, MYCN, KIF20A, BLM, GLS2, HMOX1, and GOT1. Ferroptosis linked to p53 signaling, apoptosis, and immune regulation. Molecular docking confirmed good…
brain-cancer
This review synthesizes current knowledge on methylation—affecting DNA, histones, and RNA—in pituitary neuroendocrine tumor (PitNET) biology. WHO 2022 classification puts molecular biology at the center of PitNET diagnosis. Methylation drives tumor initiation and progression through mutual…
brain-cancer
Territory-wide retrospective cohort of 274 pediatric brain tumor survivors found ADHD in 10.6% and ASD in 6.9%—significantly above general population rates. Risk factors: younger age at diagnosis, seizure history, supratentorial location, radiotherapy. Better sleep quality correlated with fewer…
brain-cancer
EA-Net uses edge attention combining Multi-Scale Context Fusion and Edge Segmentation modules to improve brain tumor boundary detection. Achieved Dice coefficients of 90.37% for Tumor Core and 88.91% for Whole Tumor on BraTS2021, with strong cross-dataset generalization.
brain-cancer
Glioblastoma (GBM) is one of the most lethal cancers, in part because it co-opts its surrounding environment to support its own growth. A Canadian research team found that certain brain cells — previously thought to only support healthy neurons — can actually promote glioblastoma growth by sending…
brain-cancer
Glioblastoma (GBM) is the most lethal brain tumor, notorious for resisting treatment. A major reason is intratumoral heterogeneity — different parts of the tumor can be biologically distinct. This study directly characterized this heterogeneity by taking multiple MRI-guided biopsies from different…
brain-cancer
Diffuse midline glioma (DMG) is one of the most devastating childhood brain cancers, with almost no effective treatments. This study investigated how neurotransmitter signaling and epigenetic mechanisms might be targeted in combination to fight this cancer.
brain-cancer
Key regulatory axis keeps brain cancer stem cells alive and fuels drug resistance in childhood brain tumors Sonic Hedgehog medulloblastoma (SHH-MB) is a brain tumor that can relapse after treatment, driven by stem/progenitor-like cells that resist chemotherapy. Understanding what maintains these cells is critical to preventing relapse. This study